icapamespib (PU-AD) / Samus Therap  >>  Phase 1
Welcome,         Profile    Billing    Logout  

3 Trials

Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
icapamespib (PU-AD) / Samus Therap
Glio, NCT04782609: Study of Icapamespib (PU-AD) in Patients With Recurrent Malignant ma

Terminated
1b
7
US
Icapamespib, Malignant Glioma
Samus Therapeutics, Inc.
Recurrent Glioblastoma Multiforme (GBM), Grade 3 Isocitrate Dehydrogenase (IDH) Wildtype Astrocytoma, Grade 3 or 4 Astrocytoma, Glioblastoma Surgery
11/22
11/22
NCT03371420: PET Imaging of Subjects Using 124I-PU-AD

Terminated
1
5
US
PU-AD, PET Scan, Blood Draws
Samus Therapeutics, Inc., Memorial Sloan Kettering Cancer Center, Weill Medical College of Cornell University, Rockefeller University
Lymphoma, Solid Malignancy, Alzheimer Disease, Myeloma
06/19
06/19
NCT03935568: A Single and Multiple Ascending Dose Study to Evaluate the Safety and Pharmacokinetics of PU-AD in Healthy Subjects

Terminated
1
40
US
PU-AD, Placebo
Samus Therapeutics, Inc.
Alzheimer's Disease
12/19
12/19

Download Options